Ayşen DİZMAN, Gökçe Kaan OLCAY, Yıldız YÜKSELEN GÜNEY, Ela DELİKGÖZ SOYKUT, Süheyla AYTAÇ ARSLAN, Sibel ÖZDOĞAN, Mehmet Faik ÇETİNDAG, Rahmi DUMAN, Mehmet BALCI

Fraksiyone stereotaktik radyoterapi ile tedavi edilen uveal melanom hastalarının retrospektif olarak değerlendirilmesi

Amaç: Son yıllarda, radyoterapi uveal melanom tedavisinde tümör çapı ve yerleşimi uygunsa etkili bir organ koruyucu yöntem olarak cerrahinin yerini almıştır. CyberKnife fraksiyone stereotaktik radyoterapi ile tedavi edilen uveal melanom olgularındaki deneyimimizi rapor etmeyi amaçladık. Yöntem: CyberKnife fraksiyone stereotaktik radyoterapi ile tedavi edilen 31 uveal melanom olgusu retrospektif olarak değerlendirildi. 29 hastada tümör boyutu orta, 2 hastada ise büyük boyutluydu. Bulgular: Ortanca takip süresi 26 aydı. Genel sağkalım, metastazsız sağkalım, lokal kontrol ve göz korunma oranları 2- ve 4- yıl için sırasıyla %97.4, %94.7; %89.1, %81; %92.9, %81.3 ve %82.1, %61.9’du. Sonuç: Deneyimlerimiz ışığında, uveal melanom hastalarında CyberKnife fraksiyone stereotaktik radyoterapi kullanımı noninvaziv, hassas bir radyoterapi yöntemi olarak tercih edilebilir.

Retrospective review of uveal melanoma patients treated with fractionated stereotactic radiotherapy

Objective: Last decades, radiotherapy displaced surgery as an effective organ preserving option for uveal melanomatreatment if tumor diameter and localisation permits. We aimed to report our experience about the management of uvealmelanoma treated with CyberKnife fractionated stereotactic radiotherapy.Method: We retrospectively evaluated 31 uveal melanoma patients treated with CyberKnife fractionated stereotacticradiotherapy. 29 was medium and 2 was large sized tumor.Results: The median follow-up was 26 months. Overall survival, metastasis free survival, local control and eyeretention rates for 2- and 4-year were 97.4%, 94.7%; 89.1%, 81%; 92.9%, 81.3% and 82.1%, 61.9%, respectively.Conclusions: In view of our experience, it may be preferable to use CyberKnife fractionated stereotactic radiotherapyfor patients with uveal melanoma as a noninvasive, precise radiotherapy technique.

PDF

___

Virgili G, Gatta G, Ciccolallo L et al. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol 2008;126: 1413-8.
Singh AD, Topham A. Incidence of uveal melanoma in the United States:1973-1997. Ophthalmology 2003;110: 956-61.
Greven KM, Greven CM. Orbital, ocular and optic nerve tumors. In: Tepper JE, Gunderson LL (eds). Clinical Radiation Oncology, third edn. Philedelphia: Elsevier Publishers, 2012; 535.
Zimmerman LE. Changing concepts concerning the malignancy of ocular tumors. Arch Ophthalmol 1967;78: 166-73.
Freire JE, Kolton MM, Brady LW. Eye and Orbit. In: Halperin EC, Perez C , Brady LW (eds). Perez and Brady’s Principles and Practice of Radiation Oncology, fifth edn. Philadelphia: Lippincott Williams &Wilkins Publishers, 2008; 783.
Zimmerman LE, McLean IW, Foster WD. Statistical analysis of follow-up data concerning uveal melanomas, and the influence of enucleation. Ophthalmology 1980;87: 557-64.
The Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001;119: 969-82.
The Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, V: Twelve-year mortality rates and prognostic factors. COMS Report No. 28. Arch Ophthalmol 2006;124: 1684-93.
Wang Z, Nabhan M, Schild SE et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Biol Phys 2013;86: 18-26.
Langmann G, Pendl G, Klaus M, Papaefthymiou G, Guss H. Gamma Knife radiosurgery for uveal melanomas: an 8-year experience. J Neurosurg 2000;93(Suppl 3): 184-8.
Dunavoelgyi R, Dieckmann K, Gleiss A et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 2011;81: 199-205.
Caujolle JP, Mammar H, Chamorey E et al. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years’ experience. Int J Radiat Oncol Biol Phys 2010;78: 98-103.
Char DH, Quivey JM, Castro JR, Krol S, Philips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993;100: 1547-54.
Langmann G, Pendl G, Mullner K, Feichtinger KH, Papaefthymiouaf G. High-compared with low-dose radiosurgery for uveal melanomas. J Neurosurg 2002;97(Suppl 5): 640-3.
Fakiris AJ, Lo SS, Henderson MA et al. Gamma Knife-based stereotactic radiosurgery for uveal melanoma. Stereotact Funct Neurosurg 2007;85: 106-12.
Mueller AJ, Talies S, Schaller UC et al. Stereotactic radiosurgery of large uveal melanomas with Gamma Knife. Ophthalmology 2000;107: 1381-1387, discussion 1387-8.
Modorati G, Miserocchi E, Galli L, Picozzi P, Rama P. Gamma Knife radiosurgery for uveal melanoma: 12 years of experience. Br J Ophthalmol 2009;93: 40-4.
Tokuuye K, Akine Y, Sumi M et al. Fractionated stereotactic radiotherapy for choroidal melanoma. Radiother Oncol 1997;43: 87-91.
Muacevic A, Nentwich M, Wowra B et al. Development of a streamlined, non-invasive robotic radiosurgery method for treatment of uveal melanoma. Technol Cancer Res Treat 2008;7: 369-74.
Choi SY, Kim MS, Yoo SY et al. Feasibility of image-guided robotic radiotherapy using three fractions for uveal melanoma. Tumori 2009;95: 720-5.
Zorlu F, Selek U, Kiratli H. Initial results of fractionated CyberKnife radiosurgery for uveal melanoma. J Neurooncol 2009;94: 111-7.
Kidd MN, Lyness RW, Patterson CC, Johnston PB, Archer DB. Prognostic factors in malignant melanoma of the choroid: a retrospective survey of cases occurring in Northern Ireland between 1965 and 1980. Trans Ophthalmol Soc U K 1986;105: 114-21p.
Greven KM, Greven CM. Orbital, ocular and optic nerve tumors. In: Tepper JE, Gunderson LL (eds). Clinical Radiation Oncology, third edn. Philedelphia: Elsevier Publishers, 2012; 534.
Gragoudas ES, Lane AM, Regan S et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000;118: 773-8.
Cohen VM, Carter MJ, Kemeny A, Radatz M, Rennie IG. Metastasis-free survival following treatment for uveal melanoma with either stereotactic radiosurgery or enucleation. Acta Ophthalmol Scand 2003;81: 383-8.
Furdova A, Slezak P, Chorvath M et al. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma. Neoplasma 2010;57: 377-81.
Nag S, Quivey JM, Earle JD et al. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003;56: 544-55.
Daftari IK, Petti PL, Shrieve DC, Phillips TL. Newer radiation modalities for choroidal tumors. Int Ophthalmol Clin 2006;46: 69-79.
Weber DC, Bogner J, Verwey J et al. Proton beam radiotherapy versus fractionated stereotactic radiotherapy for uveal melanomas: a comparative study. Int J Radiat Oncol Biol Phys 2005;63: 373- 84.
Greven KM, Greven CM. Orbital, ocular and optic nerve tumors. In: Tepper JE, Gunderson LL (eds). Clinical Radiation Oncology, third edn. Philedelphia: Elsevier Publishers, 2012; 538.
Kaprealian T, Mishra KK, Wang-ChesebroA, Quivey JM. Malignant and Benign Diseases of the Eye and Orbit. In: Hansen EK, Roach M (eds). Handbook of Evidence-Based Radiation Oncology, second edn. New York: Springer Publisher, 2010; 82-4.
Zehetmayer M. Stereotactic photon beam irradiation of uveal melanoma. Dev Ophthalmol 2012;49: 58-65.
Damato B. Does ocular treatment of uveal melanoma influence survival? British Journal Canc 2010;103: 285-90.
Sarici AM, Pazarli H.Gamma-knife-based stereotactic radiosurgery for medium- and large sized posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2013;251: 285-94.
Al-Wassia R, Dal Pra A, Shun K et al. Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience. Int J Radiat Biol Phys 2011;81: 455-62.
Logani S, Cho AS, Su LD et al. Effects of gamma radiation on the OM431 human ocular melanoma cell line. Exp Eye Res 1995;60: 603-5.
Soulieres D, Rousseau A, Tardif M et al. The radiosensitivity of uveal melanoma cells and the cell survival curve. Graefes Arch Clin Exp Ophthalmol 1995;233: 85-9.
van den Aardweg GJ, Naus NC, Verhoeven AC, de Klein A, Luyten GP. Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2002;43: 2561-5.
van den Aardweg GJ, Kiliç E, de Klein A, Luyten G. Dose fractionation effects in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2003;44: 4660-4.
Rennie I, Forster D, Kemeny A, Walton L, Kunkler I. The use of single fraction Leksell Stereotactic radiosurgery in the treatment of uveal melanoma. Acta Ophthalmology 1996;74: 558-62.
Zehetmayer M, Kitz K, Menapace R et al. Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol 2000;55: 135-44.
Simonova G, Novontny J, Liscak R, Pilbauer J. Leksell Gamma Knife treatment of uveal melanoma. J Neurosurg 2002;97(Supll 5): 635-9.
Haas A, Pinter O, Papaefthymiou G et al. Incidence of radiation retinopathy after highdosage single fraction Gamma Knife radiosurgery for choroidal melanoma. Ophthalmology 2002;109: 909-13.
Freire JE, Kolton MM, Brady LW. Eye and Orbit. In: Halperin EC, Perez C , Brady LW (eds). Perez and Brady’s Principles and Practice of Radiation Oncology, fifth edn. Philadelphia: Lippincott Williams &Wilkins Publishers, 2008; 786.
Bell DJ, Wilson MW. Choroidal melanoma: natural history and management options. Cancer Control 2004;11: 296-303.